In mice, obesity reduced bone thickness while insulinopenic type 2 diabetes decreased trabecular number and bone stiffness, with diabetes-related bone damage correlating with reduced circulating levels of the antimicrobial peptide CRAMP.
CRAMP drops in diabetes, not obesityCirculating antimicrobial peptide CRAMP decreased specifically in insulinopenic diabetic mice with impaired bone quality, not in obese mice
What the researchers found
Hyperinsulinemic obesity decreased trabecular and cortical bone thickness with BMAT expansion but preserved CRAMP levels. Insulinopenic T2D decreased trabecular number, impaired bone stiffness, and reduced circulating CRAMP peptide levels, suggesting a link between insulin deficiency, bone quality, and innate immune peptide regulation.
Why it matters
Both obesity and diabetes increase fracture risk, but through different mechanisms. Understanding that the antimicrobial peptide CRAMP is specifically reduced in insulinopenic diabetes—not obesity—could reveal new biomarkers for diabetes-related bone fragility and potential therapeutic targets at the intersection of innate immunity and bone health.
The numbers in context
C57BL/6J male mice on high-fat diet (16 weeks) for obesity model. Streptozotocin + HFD for insulinopenic T2D model. Compared to low-fat diet controls. Assessed bone phenotype and bone marrow adipose tissue.
How the study worked
Controlled animal study using C57BL/6J male mice with high-fat diet (HFD) for obesity and HFD + streptozotocin (STZ) for insulinopenic T2D, assessed over 8-16 weeks via micro-CT bone analysis, biomechanical testing, BMAT quantification, and serum CRAMP measurement.
Who was studied
C57BL/6J male mice with diet-induced obesity or STZ-induced type 2 diabetes
What this study cannot tell us
Mouse model only—STZ-induced diabetes does not perfectly replicate human T2D pathophysiology. Only male mice studied. Correlation between CRAMP reduction and bone changes does not establish causation. Human cathelicidin (LL-37) may behave differently than mouse CRAMP.
How to read the evidence
Well-controlled preclinical study with appropriate disease models and comprehensive bone analysis. Novel finding linking CRAMP to diabetic bone disease, but mechanistic pathways and human relevance need confirmation.
When this study was published
Published in 2025; represents emerging research on antimicrobial peptides in metabolic bone disease.
The bigger picture
This study connects two growing research areas—peptide-based innate immunity and metabolic bone disease. The finding that CRAMP (the mouse equivalent of human LL-37) is specifically downregulated in diabetic bone disease opens questions about whether antimicrobial peptides serve dual roles in immune defense and metabolic bone health.
Questions still open
- Could restoring CRAMP/LL-37 levels protect bone quality in diabetic patients?
- Is circulating LL-37 reduced in human type 2 diabetes and does it correlate with fracture risk?
- What molecular pathway connects insulin deficiency to CRAMP peptide downregulation?
Common questions
What is CRAMP and why is it relevant to bone health?
Does obesity or diabetes cause worse bone damage?
Read the original research
Obesity and insulinopenic type 2 diabetes differentially impact, bone phenotype, bone marrow adipose tissue, and serum levels of the cathelicidin-related antimicrobial peptide in mice.
Bone, 193, 117387
Citation
Paquet, Amélie; Bahlouli, Nadia; Coutel, Xavier; Leterme, Damien; Delattre, Jérôme; Gauthier, Véronique; Miellot, Flore; Delplace, Séverine; Rouge-Labriet, Hélène; Bertheaume, Nicolas; Chauveau, Christophe; Benachour, Hamanou. (2025). Obesity and insulinopenic type 2 diabetes differentially impact, bone phenotype, bone marrow adipose tissue, and serum levels of the cathelicidin-related antimicrobial peptide in mice.. Bone, 193, 117387. https://doi.org/10.1016/j.bone.2024.117387